Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Chelatexx (Reformulated Orlistat)

M&A STATUS
M&A LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Manufacturer of C-103, a reformulated version of orlistat for weight management. Orlistat is marketed in prescription strength by Roche Laboratories (Xenical(R) 120mg capsules) and in over-the-counter strength by GlaxoSmithKline Consumer Healthcare (alli(R) 60mg capsules). Orlistat is an FDA-approved weight management drug for a pediatric population (adolescents 12 years and older).

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Acquirer
Primary Office
  • 110 Stanbery Ridge
  • Fort Thomas, KY 41075
  • United States

Chelatexx (Reformulated Orlistat) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Chelatexx (Reformulated Orlistat)‘s full profile, request access.

Request full access to PitchBook

Chelatexx (Reformulated Orlistat) Executive Team (1)

Name Title Board
Seat
Contact
Info
Gary Thompson President & Chief Executive Officer